Home Medical News Amicus Therapeutics receives U.S. approval for Fabry disease drug

Amicus Therapeutics receives U.S. approval for Fabry disease drug

8
0
SHARE



August 10, 2018 / 8:39 PM / Updated 10 minutes ago

Amicus Therapeutics receives U.S. approval for Fabry disease drug

(Reuters) – U.S. health regulators on Friday approved Amicus Therapeutics’ Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Galafold, known chemically as migalastat, will be the first new Fabry treatment on the U.S. market in over 15 years, and will compete with Sanofi’s infused Fabrazyme.

Reporting by Robin Respaut; Editing by Phil Berlowitz




Source link

SHARE
Previous articleAlgorithm IDs Patients at Risk of Post-MI Events
Next article‘Snapchat Dysmorphia’: Seeking Selfie Perfection
Dr Irfanullah Khan Born: 15th July,1994 in Khagram,Dir Upper KPK Pakistan. Others names:Doctor Irfo,Peshoo Education:Pharm-D Scholar Graduated from Abasyn University Peshawar. Occupation:Clinical Pharmacist,Doctor,Entrepreneur. Home Town:Dir Upper Height: 6 feet. Website:Iukmedonline.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here